Remove Diabetes Remove Drug Development Remove Drug Pricing
article thumbnail

STAT+: U.K. agency declines to recommend Eli Lilly’s Mounjaro for type 2 diabetes

STAT

government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence. LONDON — A U.K. Mounjaro, also known as tirzepatide, has U.S.

Diabetes 241
article thumbnail

Can GLP-1 drugs help with type 1 diabetes?

STAT

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning, and congratulations on making it through another week. She is very likely the cutest and most relatable animal I’ve ever seen.

Diabetes 287
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Consumer and labor groups urge FTC to block Catalent sale to Novo Holdings

STAT

billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition will harm competition and reduce patient access to popular diabetes and weight loss medicines.

Diabetes 276
article thumbnail

The findings from Alnylam’s highly anticipated readout  

STAT

On top of today’s Alnylam news, we have Congress gearing up to vote on Medicare coverage for multi-cancer screenings and obesity drug coverage. Also, updates on Vertex’s type 1 diabetes cell therapy, and a push for phage therapy. Read the rest…

Diabetes 230
article thumbnail

More tumult at BIO amid the company’s fourth CEO in four years

STAT

Also, the agency’s advisers debate Guardant’s colon cancer liquid biopsy test, and we see new data showing Ozempic’s efficacy in preventing death in diabetes and chronic kidney disease patients. Read the rest…

Diabetes 252
article thumbnail

STAT+: Pharmalittle: We’re reading about Lilly lawsuits, Novo Nordisk fires and much more

STAT

With the immense demand for GLP-1-based drugs and recurring shortages of the branded treatments, a wide variety of businesses have popped up to offer their own versions of what they claim are GLP-1 drugs. No other company has bid on the contract — to supply 14 million pens for the next three years, at about $2 per pen. The

Diabetes 279
article thumbnail

STAT+: Pharmalittle: We’re reading about AstraZeneca CEO pay, alternatives to WuXi and more

STAT

Enjoy, and see you soon… Western drug makers are talking to alternative suppliers in response to draft U.S. legislation seeking to restrict an important Chinese drug developer and manufacturer over national security concerns , The Financial Times explains. But be safe. The Biosecure Act would prohibit U.S.